- Case Report
- Open Access
Prenatal manifestation and management of a mother and child affected by spondyloperipheral dysplasia with a C-propeptide mutation in COL2A1: case report
© Bedeschi et al; licensee BioMed Central Ltd. 2011
- Received: 18 November 2009
- Accepted: 28 February 2011
- Published: 28 February 2011
It is not unusual for patients with "rare" conditions, such as skeletal dysplasias, to remain undiagnosed until adulthood. In such cases, a pregnancy may unexpectedly reveal hidden problems and special needs. A 28 year old primigravida was referred to us at 17 weeks for counselling with an undiagnosed skeletal dysplasia with specific skeletal anomalies suggesting the collagen 2 disorder, spondyloperipheral dysplasia (SPD; MIM 156550).
She was counselled about the probability of dominant inheritance and was offered a prenatal diagnosis by sonography. US examination at 17, 18 and 20 weeks revealed fetal macrocephaly, a narrow thorax, and shortening and bowing of long bones. The parents elected to continue the pregnancy. At birth the baby showed severe respiratory distress for four weeks which then resolved. Mutation analysis of both mother and child revealed a hitherto undescribed heterozygous nonsense mutation in the C-propeptide coding region of COL2A1 confirming the diagnosis of SPD while reinforcing the genotype-phenotype correlations between C-propeptide COL2A1 mutations and the SPD-Torrance spectrum. This case demonstrates the importance of a correct diagnosis even in adulthood, enabling individuals affected by rare conditions to be made aware about recurrence and pregnancy-associated risks, and potential complications in the newborn.
- Club Foot
- Skeletal Dysplasia
- COL2A1 Gene
Type II collagenopathies range from lethal forms (Achondrogenesis II, Hypochondrogenesis), to severe diseases (spondyloepiphyseal dysplasia congenital, Kniest dysplasia) to mild phenotypes (Stickler dysplasia, a mild dominant spondyloarthropathy) . Heterozygous mutations mapping to different parts of the triple helical domain of the COL2A1 gene have been identified for most of these disorders. Spondyloperipheral dysplasia (SPD-OMIM 156550) is a skeletal dysplasia with platyspondyly and brachydactyly E changes, first described in 1977 . Additional cases were later reported with some similarities but with considerable clinical variability [3–5] but all of them exhibited autosomal dominant inheritance with duplications, truncating mutations and missense mutations of C-propeptide of the COL2A1 gene having been previously reported [4–6]. Here we describe a family, a mother and her son, with SPD and a novel truncating mutation in the C-propeptide domain of COL2A1.
Patient 1, the mother, is the first girl of healthy, non-consanguineous Caucasian parents who was spontaneously delivered at term after an uneventful pregnancy. Family history was unremarkable for mental retardation or birth defects.
Her growth parameters were always below the 3rd centile and she reached her final height of 115 cm at 16 years old. At 2 months she underwent surgical correction of club feet.
At 15 years old a diagnosis of Dyggve-Melchior-Clausen (DMC) syndrome was made in another Centre and the parents were advised accordingly. She was diagnosed with bilateral otosclerosis at 16 years and underwent a tympanum replacement in the left ear. She has had mild conductive hypoacusia since then. She developed moderate scoliosis and suffered intermittent back pain and hip and knee stiffness. Despite these medical problems, she was healthy and she had an active life.
At time of her first pregnancy she was referred to our Centre at 17 weeks of gestation following a sonogram which had revealed a fetal femur length below the 3rd centile.
Except for the presence of the brachydactyly, many of the patient's clinical and radiographic features were compatible with a type II collagen disorder, in particular with spondyloepiphyseal dysplasia congenita or Kniest dysplasia. Specifically, our patient demonstrated a number of similarities with the cases described by Zankl et al 2004  which had been used to define SPD.
During the pregnancy, the woman was offered a complete workup including a cardiac, pneumological, orthopaedic and obstetric examinations every month from the 17th to the 32nd week. All parameters remained within the normal range.
She reported a reasonably good quality of life during the second trimester but in the 32nd week she was admitted to the hospital to induce foetal lung maturation by corticosteroids.
The baby, a male, was born through a transverse caesarean section performed at the 33rd week under spinal anesthesia.
Patient 2, the child had the following measurements at birth: weight 1780 gr (10-25th centile), length 32 cm (-4 DS) and OFD 32 cm (75th centile). Apgar scores were 3, 7 and 8 at one, five and ten minutes respectively. Because of difficulties with respiration a naso-tracheal tube was inserted and breathing was aided by mechanical ventilation. The child was initially treated with a high-frequency ventilation for one day and with conventional mechanical ventilation for 12 days. For the following 25 days the child was maintained in nasal Continuous Positive Airway Pressure (CPAP). Oxygen therapy was discontinued at 41 weeks of age. A single dose of exogenous surfactant was administered. Afterwards occasional desaturation episodes were noted with spontaneous resolution. Enteric feeding was initiated on the second day of life and was maintained until week 38 when the baby was started on bottle feeding.
After informed consent was obtained from both individuals, blood was drawn and genomic DNA of both mother and son was extracted from peripheral blood leukocytes using standard protocols.
Coding regions, intron-exon boundaries and flanking intronic sequences of the COL2A1 gene were amplified by PCR. Amplified PCR products were monitored on 1.5% agarose gels.
PCR products were subjected to a denaturing step of 2 minutes at 96°C followed by gradual annealing. The annealing time of each cycle was 30 seconds followed by 50 cycles of cooling from 96°C to 46°C with a decremented gradient temperature of 1°C then 7 minutes at room temperature, to promote heteroduplex formation.
dHPLC analysis was performed using the Wave MD4000 Transgenomic® device and analysis of the results was carried out by Navigator® version 1.6.4 software.
Fragments which indicated differences from a known negative control, were sequenced bidirectionally on an ABI 3100 Genetic Analyzer (Applied Biosystems).
Each mutation was confirmed by re-amplification of a second DNA product and re-sequencing.
In patients 1 and 2 we identified a heterozygous nonsense mutation (c.4339 A > T) in exon 54, which resulted in a premature stop codon at amino acid 1447 (K1447X). (Exon and nucleotide numbering based on RefSeq NM_001844, starting at the ATG translation initiation codon).
This study describes a mother and her son, affected by severe dwarfism, peculiar facial features, similar radiological findings including shortened tubular bones, specific vertebral alterations being pear-shaped in infancy and platyspondylic by adulthood; metaphyseal and epiphyseal alterations and brachydactyly E. Even though our patient presented with the typical radiological features of type 2 collagenopathy, she was not correctly diagnosed until age 28 years.
This misidentification induced a series of consequences ranging from an incorrect knowledge of reproductive risk, a poor understanding of the clinical variability of her condition and a failure to correctly identify fetal and neonatal risks. After being correctly diagnosed at the 17th week of gestation this young woman was faced with the decision either to terminate or to carry on the pregnancy and face the birth of an affected child. We believe the final decision to continue the pregnancy was supported by her good self image despite the physical diversity.
Because she decided to not to terminate it was necessary to assemble a multidisciplinary team including obstetricians, orthopaedists, cardiologists, a pneumologist and an anaesthetist to monitor cardio-respiratory and orthopaedic complications. Fortunately, the mother demonstrated a good cardio-respiratory response despite her severe dwarfism and skeletal abnormalities.
Mutation analysis of our cases revealed a hitherto undescribed, heterozygous nonsense mutation in the C-propeptide coding region of COL2A1 (c.4339 A > T, K1447X) in exon 54. Mutations of the C-propeptide of collagen II are a well established cause of type II collagenopathy associated with brachydactyly E; indeed, additional cases of SPD associated to analogous mutations of C propeptide domain of COL2A1 have been previously reported [4, 5].
Brachydactyly E associated with metaphyseal changes is the most peculiar clinical feature of C propeptide mutations of collagen type 2, which differentiate them from other types of collagenopathies. It must be remembered that brachydactyly E is not only associated with SPD, but is part of clinical picture of other type 2 collagenopathies such as Czech dysplasia and platyspondylic lethal skeletal dysplasia, Torrance type (PLSD-T).
Czech dysplasia is characterized by early-onset, progressive pseudo-rheumatoid arthritis, hearing loss starting in early adulthood, vertebral anomalies (mild platyspondyly, irregular plates reduced intervertebral distances), normal stature and short third and fourth toes. A specific typical missense mutation (R275C) in the triple helical domain of the COL2A1 gene has been identified . In contrast to Czech dysplasia, spondyloperipheral dysplasia (SPD) is characterized by short stature, clubfeet, platyspondyly, midface hypoplasia, myopia and epiphyseal dysplasia.
Platyspondylic lethal skeletal dysplasia, Torrance type (PLSD-T) is a rare form of skeletal dysplasia characterized by platyspondyly, brachydactyly and methapyseal changes. Mutations in COL2A1 have been identified in the Torrance type . While most reports of PLSD-T describe sporadic and perinatally lethal cases, patients with longer survival have been recently reported . Zankl et al. reported 8 further cases of PLSD- T and found that all had COL2A1 mutations in the C-propeptide domain. The mutational spectrum included missense, stop codon and frameshift mutations. Two of those patients, who showed the rare adult form of PLSD-T, had given birth to children with a lethal PLSD-T.
Our patient 2 showed radiological features as platyspondyly, ovoid vertebrae, delayed ossification of pubic bones, shortened and broad tubular bones with splayed and ragged metaphyses similar to a form of PLSD-T, whereas clinical and radiological features of our patient 1 overlap with SPD. This observation further supports the conclusion that SPD and PLSD-T are not two etiologically distinct entities but belong to the same continuum phenotypic spectrum.
The aetiology of the two conditions has been recently established through the findings of mutations in C-propeptide domain of COL2A1. Of note is the characterisation of the mutation in our case, a novel nonsense mutation (c.4339 A > T) in exon 54, which resulted in a premature stop codon at amino acid 1447 (K1447X). This mutation is located at the farthest 3'end of the domain analogous to the SPD and PLSD-T mutations so far detected; the specific site of these mutations seems to allow abnormal molecules to escape from mRNA decay. This evidence has led to the hypothesis that the combination of toxic effects arising from the accumulation of altered collagen chains inside the chondrocytes, diminished collagen fibril formation, and alteration of a putative signaling function of the carboxy-propeptide of type 2 collagen are the root cause of SPD and PLSD-T pathogenesis.
In conclusion this family is an excellent example of the need for a correct diagnosis in adulthood, the evidence of wide variability of these type of collagenopathies in terms of etiology and pathogenesis. Genetic counseling in these situations is very challenging and should take into account all the different aspects of rare disease.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Spranger J, Winterpacht A, Zabel B: The type II collagenopathies: a spectrum of chondrodysplasias. Eur J Pediatr. 1994, 153: 56-65.PubMedGoogle Scholar
- Kelly TE, Lichtenstein JR, Dorst JP: An unusual familial spondyloepiphyseal dysplasia: 'spondyloperipheral dysplasia'. BDOAS. 1977, 13 (3B): 149-165.Google Scholar
- Sorge G, Ruggieri M, Lachman RS: Spondyloperipheral dysplasia. Am J Med Genet. 1995, 59: 139-142.View ArticlePubMedGoogle Scholar
- Zabel B, Hilbert K, Stoss H, Superti-Furga A, Spranger J, Winterpacht A: A specific collagen type II gene (COL2A1) mutation presenting as spondyloperipheral dysplasia. Am J Med Genet. 1996, 63: 123-128.View ArticlePubMedGoogle Scholar
- Zankl A, Zabel B, Hilbert K, Wildhardt G, Cuenot S, Xavier B, Ha-Winh R, Bonafé L, Spranger J, Superti-Furga A: Spondyloperipheral dysplasia is caused by truncating mutations in the C-propeptide of COL2A1. Am J Med Genet. 2004, 129A: 144-148.View ArticlePubMedGoogle Scholar
- Hoornaert KP, Marik I, Kozlowski K, Cole T, Le Merrer M, Leroy JG, Coucke PJ, Sillence D, Mortier GR: Czech dysplasia metatarsal type: another type II collagen disorder. Eur J Hum Genet. 2007, 15 (12): 1269-75.View ArticlePubMedGoogle Scholar
- Nishimura G, Nakashima E, Mabuchi A, Shimamoto , Shimao Y, Nagai T, Yamaguchi T, Kosaki R, Ohashi H, Makita Y, Ikegawa S: Identification of COL2A1 mutations in platyspondylic skeletal dysplasia, Torrance type. J Med Genet. 2004, 41: 75-79.PubMed CentralView ArticlePubMedGoogle Scholar
- Neumann L, Kunze J, Uhl J, Stover B, Zabel B, Spranger J: Survival to adulthood and dominant inheritance of platyspondylic skeletal dysplasia, Torrance-Luton type. Pediatr Radiol. 2003, 33: 786-790.View ArticlePubMedGoogle Scholar
- Zankl A, Neumann L, Ignatius J, Nikkels P, Schrander-Stumpel C, Mortier G, Omran H, Wright M, Hilbert K, Bonafé L, Spranger J, Zabel B, Superti-Furga A: Dominant negative mutations in the C-propeptide of COL2A1 cause platyspondylic lethal skeletal dysplasia, Torrance type, and define a novel subfamily within the type 2 collagenopathies. Am J Med Genet. 2005, 133A: 61-67.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.